What Lacrima Treats: Main Uses and Benefits

Lacrima, as an ophthalmic lubricant, is a product that is commonly used to help with symptoms related to inflammatory or irritative states such as dry eye conditions (keratoconjunctivitis sicca). The goal of this therapeutic category is to provide support that helps ease the overall symptom burden. When applied, these drops may assist with the short-term symptomatic assistance often relevant in contexts involving heightened systemic burden, including:

• burning,
• irritation due to dryness of the eye, and
• provides supportive relief when symptoms interfere with routine activities.

The core function of the product is to provide temporary symptomatic relief. The drops are applied in addressing symptoms that interfere with daily functioning, such as the foreign body sensation that can occur from environmental factors or activities like extended computer use. This is often used during phases when symptoms become more noticeable. The use of Lacrima contributes to improved comfort during periods of heightened symptoms. This formulation assists with maintaining functional stability and supports the patient during difficult episodes by easing distress.

---

Quick Fact: Relief for Symptoms that interfere with daily functioning

Regulatory References

1. NIH DailyMed official drug label information

Eligibility for Lacrima

The eligibility profile for Lacrima (Dextran 70 / Hypromellose Ophthalmic Solution) is defined primarily by its local action, as documented in regulatory sources.

Populations for Whom Use is Contraindicated

Lacrima is absolutely contraindicated for individuals with a known hypersensitivity or allergy to Dextran 70, Hypromellose, or any other component in the formulation. This is the only formal exclusionary criterion based on the product’s composition.

Age-Related and Special Population Eligibility

Use is established and generally allowed for adults and older adults without specific age-based restrictions. However, use is typically not recommended or established in children under 6 years of age unless directed by a health professional.

Due to the medicine’s negligible systemic absorption, regulatory information indicates that use is acceptable during pregnancy and lactation. Similarly, there are no documented restrictions for patients with hepatic impairment or renal impairment.

Conditional Use Restrictions

Use is restricted to the temporary relief of minor symptoms. Individuals must discontinue use and seek medical advice if they experience eye pain, changes in vision, or if redness or irritation persists or worsens for more than 72 hours.

Lacrima Interactions with other medicines and products

The interaction profile for Lacrima, an ophthalmic agent containing Dextran 70 and Hypromellose, is strictly defined by its local, non-systemic use as a tear substitute and lubricant. Since the active ingredients are inert, semisynthetic polymers that are not absorbed into the bloodstream at pharmacologically relevant levels, the product does not participate in the systemic drug-drug interactions typically associated with oral medicines. This lack of systemic exposure means there are no officially documented interactions via common metabolic pathways, such as cytochrome P450 enzymes, and thus no need for warnings regarding exposure-altering effects or contraindicated combinations with systemically acting drugs.

---

Administration Timing Requirement

The only officially documented interaction constraint involves the co-administration of Lacrima with other medicines intended for topical ocular application. When used concurrently with other eye drops or ophthalmic solutions, Lacrima may cause a physical dilution or washout of the co-administered medicated product, which may compromise its local therapeutic action.

To prevent this local physical interaction, regulatory documents establish a mandatory timing rule: Lacrima must be administered at least five minutes after any other medicated ophthalmic solution. This interval ensures that the initial medicinal product has adequate time for retention and absorption before the lubricant solution is applied. The profile does not specify population-dependent interaction notes.

Lacrima is an antibody that binds with high affinity to the IL-17A receptor subunit. This binding results in the steric hindrance of ligand-receptor interaction, effectively blocking the receptor. This action prevents the IL-17A-mediated T H17 intracellular signal transduction cascade.

The blockade of IL-17A signaling downregulates the activity of the transcription factor NF-kappa B and associated kinase activity within target cells. This process consequently alters the stoichiometry of various associated signaling complexes.

The resulting mechanistic cascade leads to a shift in the RANKL/ OPG ratio toward OPG and reduces the activity of pro-osteoclastogenic cytokines. This action primarily modulates skeletal structure by attenuating NF-kappa B signaling and decreasing osteoclastogenesis (the formation of bone-resorbing cells).

Administration Guidelines for Lacrima

Lacrima is an oral medication with dosing and administration rules defined to ensure proper use. The treatment course requires monitoring of blood cell counts before initiation.

Dosage and Frequency

The recommended total daily dose is 50 mg/kg/day, with a maximum daily dose not exceeding 3,000 mg. This total daily amount must be divided and administered in either 2 or 3 doses per day, depending on the patient's age and weight, for individuals 6 months of age and older weighing 7 kg or more. Specific age and weight-based division instructions are provided in the prescribing information.

Procedural Requirements

Lacrima must be taken during a meal.

Formulation	Preparation and Administration
Capsules	Must be swallowed whole with water. Do not crush, break, or open the capsule.
Powder for Oral Suspension	Mix the entire packet contents into a glass containing 100 mL of water and drink immediately. To ensure the full dose is received, add an additional 25 mL of water to the glass, stir, and consume again.

Missed Dose Instructions

If a dose is missed, it should be taken as soon as possible. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped entirely; doses should not be doubled to compensate.

---

The instruction set provides a clear sequence for the oral delivery of Lacrima, tying the timing of ingestion to meals and detailing the specific preparation steps required for both capsule and suspension forms. These guidelines define the route, frequency, and preparation for its correct use.

Research Evidence: Overview of Studies for Lacrima

This section describes the types of clinical research and outcomes that were studied for lubricant ophthalmic products containing Dextran 70 and Hypromellose. The information presented here focuses on group patterns observed in studies and does not provide individual medical predictions or advice. This overview is based on research as referenced in regulatory documents and peer-reviewed scientific literature.

Evidence for use in Temporary Relief of Mild to Moderate Dry Eye Symptoms

The primary research base for this combination includes short-term Randomized Controlled Trials (RCTs) that were designed to study the formulation against a vehicle (placebo) or against other existing artificial tears. These studies were used in research exploring how symptoms change over time in people with mild to moderate dry eye.

Researchers examined what patients reported about their eye comfort, using specific questionnaires that measure patient-reported outcomes describing perceived discomfort, such as burning, foreign body sensation, and dryness severity. Studies also monitored objective clinical measures related to the eye's physical function, such as the Tear Film Break-up Time (TBUT).

Findings describe patterns observed in the studies over time where people reported changes in their overall symptom experience. Research also describes changes measured during the study period for objective signs like TBUT. However, the research also includes studies where results were examined alongside data from other types of artificial tears, and the findings were mixed or varied across studies, particularly for the objective measurements.

---

Long-term Research and Follow-up Durations

The clinical trials conducted for this class of product typically focus on research exploring short-term symptom changes, often tracking patients for periods of four weeks or less. This short-term follow-up duration was used in research exploring short-term or episodic symptom patterns.

However, the question of long-term effects remains less clear. The long-term effects are not fully established because the follow-up durations were limited. There is currently limited information for long-term outcomes regarding the sustained use of the formulation over periods exceeding several months.

---

What the Research Gaps Indicate is Still Uncertain

Research has highlighted what is known — and what is still uncertain about the use of these drops. One of the main uncertainties centers on the inconsistencies in findings that were mixed regarding objective clinical signs when results were studied alongside data from other established products.

A key research gap is that long-term effects are not fully established because the follow-up durations were limited. Additionally, comparative evidence is lacking for many specific over-the-counter polymer combinations beyond short-term assessments. This means the research provides context but not individual predictions, and more research is ongoing to better understand the long-term symptomatic and physiological patterns in patients using this class of product.

Key Studies & References

1. Dextran 70 and Hypromellose Ophthalmic Solution (Lacrima) - FDA DailyMed
2. Methodological quality and outcome parameters of controlled clinical trials for dry eye treatments: a systematic review

Common questions about Lacrima (FAQ)

---

Q: What is the difference between Lacrima and other similar eye drops?

A: According to official product information, Lacrima is characterized by its dual-polymer system, combining Dextran 70 and Hypromellose. This specific formulation is described as a dual-polymer system designed to support the stability and thickening of the tear film.

---

Q: Is it normal to feel a slight stinging sensation right after using Lacrima?

A: Official labeling notes that minor and transient burning, stinging, or irritation may occur when a person first applies this type of ophthalmic product. This sensation is typically mild and is considered a common, temporary reaction.

---

Q: Can Lacrima cause blurred vision temporarily?

A: Yes, regulatory documents indicate that transient blurring of vision can occur shortly after the drops are applied. Regulatory precautions indicate that activities requiring clear vision, such as driving or operating machinery, should be avoided until the transient blurring resolves.

---

Q: Does using Lacrima regularly improve chronic dry eye over time?

A: Studies and official information indicate that the primary research base for this type of product focuses on short-term symptom changes and temporary relief. The research base focuses on temporary relief, and the long-term effects of sustained use for chronic conditions are not fully established by regulatory-cited clinical data.

---

Q: Does Lacrima help with redness or only with dryness?

A: Lacrima is primarily indicated for the temporary relief of discomfort and dryness. The primary indication is relief from dryness and irritation; some regulatory information may note that certain forms of redness are reported to improve in related studies, or are listed as potential side effects.

---

Q: Can I use Lacrima long-term?

A: Official information regarding the product's long-term use is limited. The clinical trials reviewed by regulators typically focused on short-term follow-up durations, such as four weeks or less. Therefore, long-term effects of use over many months are not fully established based on the data cited by regulatory authorities.

---

Q: Why do some people experience watery eyes after using Lacrima?

A: Increased tearing, also known as lacrimation or watery eyes, has been reported as an adverse reaction following the application of this type of ophthalmic agent. This is a documented response to the product's use.

---

Q: How quickly should I expect Lacrima to start working?

A: Lacrima is a non-pharmacological lubricant that works by physically augmenting the tear film. Official sources indicate that the relief from dryness and discomfort is generally considered temporary and immediate upon application to the eye's surface.

---

Q: Does Lacrima help with eye strain from screens?

A: The product is officially indicated for the temporary relief of discomfort due to minor irritations caused by exposure to environmental factors like wind or sun. While official labeling doesn't specifically mention screen use, eye strain from screens is a similar external irritant that may be addressed by the product's lubricating action.

---

Q: Are there different strengths or formulations of Lacrima available?

A: According to regulatory labeling on dosage forms and strengths, Lacrima is typically supplied as a single Ophthalmic Solution formulation. This product contains the specified, fixed concentrations of Dextran 70 and Hypromellose.

---

Q: Are there specific vitamins or supplements that interact with Lacrima?

A: No officially documented systemic drug-drug interactions with vitamins or supplements are expected. This is because the active ingredients are inert, non-systemic polymers that act only on the eye's surface and are not absorbed into the bloodstream at levels that would affect systemic metabolism.

---

Q: How can I tell if Lacrima is actually working for my condition?

A: Official information suggests that effectiveness is generally associated with the temporary relief of dry eye symptoms such as reduced burning, scratching, or dryness, which are the primary indications.

---

Q: Is it safe to drive immediately after using Lacrima?

A: Regulatory precautions indicate that activities requiring full visual clarity should be avoided immediately after use. This is because the drops may cause a transient blurring of vision.

How to Store and Dispose of Lacrima (Dextran 70 and Hypromellose Ophthalmic Solution)

Lacrima must be stored at room temperature, typically defined by regulatory agencies as 15° to 30°C (59° to 86°F). The product must be protected from extreme temperatures; therefore, do not refrigerate and do not freeze the solution. The container should be kept tightly closed after each use.

To prevent contamination, the contents must be discarded one month (28 days) after the bottle is first opened. Always check the solution and do not use it if it changes color or becomes cloudy. As with all medicines, it must be kept out of the reach and sight of children. Expired or unused solution should not be disposed of in household waste or flushed down the toilet, but must be discarded according to local pharmaceutical disposal guidelines.